2023-07-21 11:17:38 ET
Chinese biotech BeiGene ( NASDAQ: BGNE ) said that its drug tislelizumab has received a positive opinion from an advisory committee of the European Medicines Agency for the treatment of advanced or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy.
BeiGene is co-developing the drug with Swiss drugmaker Novartis ( NVS ) in several markets, including the European Union. EMA regulators are also reviewing tislelizumab for the treatment of non-small cell lung cancer.
More on BeiGene:
- BeiGene wins FDA review to expand Brukinsa label for lymphoma
- AbbVie files patent lawsuit over BeiGene’s cancer drug - Bloomberg
- Heated Market For Dueling Blood Cancer Drugs Lands BeiGene In Court
- BeiGene Faces Patent Battle: Confronting Uncertainty In The Oncology Market
For further details see:
BeiGene drug gets positive EMA panel opinion for esophageal cancer